Welcome to our dedicated page for U S Physical Therapy SEC filings (Ticker: USPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
U.S. Physical Therapy, Inc. (USPH) files a range of reports with the U.S. Securities and Exchange Commission that document its operations as a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services. These SEC filings provide detail on its physical therapy operations segment, industrial injury prevention services, clinic additions and closures, financial performance, and capital allocation decisions.
On this Stock Titan page, investors can review U.S. Physical Therapy’s current reports on Form 8-K, which have recently covered topics such as acquisitions of multi-clinic physical therapy practices and management services companies, quarterly earnings results, dividend declarations, investor presentations, and research reports. For example, the company has filed 8-Ks describing acquisitions of a three-clinic physical therapy practice and a physical therapy management services company that manages a practice with eight clinic locations, as well as 8-Ks reporting results for specific quarters and announcing quarterly cash dividends.
In addition to 8-Ks, U.S. Physical Therapy files annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide segment information for physical therapy operations and industrial injury prevention services, along with discussions of revenue, operating costs, gross profit, and key operating metrics such as total patient visits and net rate per patient visit. These filings also include information about the company’s credit facilities, interest expense, and tax provisions.
Stock Titan enhances access to these documents by offering real-time updates from the SEC’s EDGAR system and AI-powered summaries that explain the contents of lengthy filings. Users can quickly see the main points from U.S. Physical Therapy’s 10-K and 10-Q reports, as well as key disclosures from 8-Ks related to acquisitions, earnings, and dividends. This page also serves as a starting point for reviewing any insider transaction reports on Form 4 that may be filed for USPH, alongside the company’s broader regulatory history.
US Physical Therapy Inc (USPH) Form 144 notice: The filing reports a proposed sale of 600 shares of Common stockaggregate market value of $49,026, planned for approximately 09/11/2025 on the NYSE. The shares were acquired by vesting: 1,653 shares vested on 08/20/2025 from restricted stock grants issued between 05/16/2023 and 05/20/2025, with the acquisition characterized as payment for services rendered. The filing also discloses a prior sale of 400 shares on 06/12/2025 by Nancy Ham, generating $31,204 in gross proceeds. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Eric Joseph Williams, President and COO of U S Physical Therapy, reported a sale of 1,000 shares of the company’s common stock on 09/05/2025 at $85.25 per share. After the sale he beneficially owns 25,331 shares, which include 18,210 restricted shares subject to a multi-year vesting schedule if he remains an employee. The restricted shares vest in tranches between November 20, 2025 and March 6, 2029 as specified in the filing. The Form 4 was signed by an attorney-in-fact on 09/08/2025.
USPH Form 4: Christopher J. Reading, Chairman and CEO of U S Physical Therapy Inc (USPH), reported a single transaction on 09/04/2025 selling 2,000 shares of the issuer's common stock at a price of $83.53 per share. After the sale he beneficially owns 114,088 shares in total. The filing discloses that 34,098 of those shares were granted as restricted stock under the companys Amended and Restated 2003 Stock Incentive Plan, with a detailed vesting schedule listing tranche dates and share counts through March 6, 2029, contingent on continued employment.
US Physical Therapy, Inc. (USPH) reported a proposed sale of 1,000 common shares through Rule 144 to be executed on 09/05/2025 on the NYSE via Morgan Stanley Smith Barney LLC. The shares were acquired on 07/01/2024 under the company's Employee Stock Purchase Plan and were paid as compensation. The notice lists an aggregate market value of $85,250.00 for the shares and shows 15,204,119 shares outstanding for the issuer. The filer certifies they are unaware of undisclosed material adverse information and indicates no reportable securities sales in the past three months.
US Physical Therapy, Inc. (USPH) submitted a Form 144 notifying a proposed sale of 2,000 shares of common stock through UBS Financial Services on the NYSE with an aggregate market value of $165,127.20. The shares were originally acquired as restricted stock grants on 04/01/2020 (3,089 shares acquired) and were paid as compensation on the acquisition date. The filing states there were no securities sold by the reporting person in the past three months. The notice includes the required representation that the seller is not aware of undisclosed material adverse information about the issuer.
US Physical Therapy Inc. (USPH) Chief Financial Officer Carey P. Hendrickson reported a disposal of 698 shares of common stock on 08/25/2025 at an average price of $86.11 per share, leaving beneficial ownership of 27,808 shares. The filing shows Mr. Hendrickson is an officer (Chief Financial Officer) and the Form 4 was filed by one reporting person.
The reported holdings include 14,510 shares issued as restricted stock under the companys Amended and Restated 2003 Stock Incentive Plan. Those restricted shares vest in scheduled tranches from November 20, 2025 through March 6, 2029, contingent on continued employment, with specific share counts and vesting dates provided in the filing.
US Physical Therapy, Inc. (USPH) filed a Form 144 proposing the sale of 700 shares of common stock through Charles Schwab & Co., Inc. The filing lists an approximate sale date of 08/25/2025 and reports an aggregate market value of $60,119. It shows total shares outstanding of 15,204,119, indicating the proposed sale represents a very small fraction of the companys outstanding stock. The shares were acquired on 01/01/2025 as employee equity compensation (1,208 shares reported acquired). The filer reports no sales in the past three months.
US Physical Therapy, Inc. insider sale reported. The company's COO and director, Graham D. Reeve, reported the sale of 763 shares of Common Stock on 08/21/2025 at a weighted average price of $84.97 per share. After the sale he beneficially owns 21,483 shares directly and 1,808 shares indirectly through the Reeve Trust. The filing notes that 15,296 of his shares are restricted stock with a detailed vesting schedule from November 2025 through March 2029.
US Physical Therapy, Inc. (USPH) Form 144 notifies the planned sale of 763 shares of Class A Common Stock by Graham Reeve through J.P. Morgan Securities on or about 08/21/2025, with an aggregate market value listed as $64,832. The shares were acquired on 05/20/2025 through the vesting of restricted stock grants issued between 08/16/2021 and 02/24/2025. The filing shows the person intends cash payment on 08/22/2025. The issuer’s outstanding shares are reported as 15,190,000, making this sale a very small portion of total stock. The filing also discloses two prior sales by the same person within the past three months: 1,792 shares on 08/11/2025 for $155,124.48 and 530 shares on 05/21/2025 for $41,382. The signer represents they are not aware of undisclosed material adverse information about the issuer.
Richard Binstein, Executive Vice President, General Counsel & Secretary of U S Physical Therapy, Inc. (USPH), reported the sale of 2,000 shares of the issuer's common stock on 08/19/2025 at a price of $84.79 per share. After the sale he beneficially owned 17,867 shares. The filing discloses that 15,726 of those shares were granted as restricted stock under the company's Amended and Restated 2003 Stock Incentive Plan and lists the detailed vesting schedule showing incremental lapses from August 20, 2025 through March 6, 2029, contingent on continued employment on each vesting date. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person.